Angela Vollstedt
Global Director, Cell & Gene Therapies Portfolio Management at Novartis
I'm an accomplished Biotech & Pharma executive with deep expertise in science, product strategy and development and commercial life-cycle management. Focusing on Advanced Therapies (CAR-T and Gene Therapy), Oncology, Immunology, and Endocrinology, I've consistently led high-performing teams to achieve groundbreaking milestones in drug development and market success.
Key achievements include:
+ Driving CMC product design and development paving the way for successful market launch and life-cycle maintenance of Zarxio™, Omnitrope™, Hyrimoz™ and Tyruko™
+ Advancing ten projects to through early clinical development into late-stage development, including four successful BLA and life-cycle maintenance product improvement approvals.
As Director, Novartis Cell & Gene Therapies R&D Portfolio, I shape key assets’ direction and secure strategic partnering and funding to achieve critical regulatory milestones. My extensive experience enables me to forge strategic partnerships and accelerate product development.
I thrive in dynamic, entrepreneurial environments, where I design and launch products that transform clinical practice and improve patient outcomes. With a passion for driving innovation, I’ve recently completed my MBA to deepen my role in shaping the technology innovation space.
My commitment to excellence is rooted in servant leadership and a steadfast belief in focusing our collective efforts to make a lasting and sustainable impact on the lives of patients around the world. I am passionate about championing the next generation of leaders as a supporter of Youth Entrepreneurship and empowering Women in Advanced Therapies and beyond.